High dose rate brachytherapy for carcinoma of the cervix: Risk factors for late rectal complications

被引:22
作者
Uno, T
Itami, J
Aruga, M
Kotaka, K
Fujimoto, H
Sato, T
Minoura, S
Ito, H
机构
[1] Int Med Ctr, Dept Radiat Therapy & Oncol, Shinjuku Ku, Tokyo 162, Japan
[2] Int Med Ctr, Dept Gynecol, Shinjuku Ku, Tokyo 162, Japan
[3] Chiba Univ, Sch Med, Dept Radiol, Chiba 280, Japan
来源
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 1998年 / 40卷 / 03期
关键词
carcinoma of uterine cervix; radiation therapy; high dose rate brachytherapy; complications; isodose volume;
D O I
10.1016/S0360-3016(97)00849-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To determine the incidence of late rectal complications in patients treated with high dose rate brachytherapy for FIGO Stage IIB, IIIB carcinoma of the uterine cenix, and to evaluate the treatment factors associated with an increased probability of treatment complications. Methods and Materials: Records of 100 patients with FIGO IIB and IIIB cervical carcinoma treated with definitive irradiation using high dose rate intracavitary brachytherapy (HDR-ICR) between 1977 and 1994 mere retrospectively reviewed. For each HDR-ICR session, 6-Gy isodose volume was reconstructed retrospectively and the relationship between probability of late rectal complications and several treatment factors, including a specific point dose and parameters representing isodose volume, were examined. Statistical analyses were performed to determine the treatment factors predictive of late rectal complications. Results: Of patients treated for both stages, 33% and 38% had experienced moderate to severe (Grade 2-4) complications at 3 and 5 years, respectively, Mean value of depth (L)) of 6-Gy isodose volume in HDR-ICR in patients with and without complication were 51 mm and 46 mm, respectively (p = 0.0070), A significant difference was noted in complication rate between patients with D > 51 mm and D less than or equal to 51 mm (p = 0.0023), Cumulative Point S (2 cm dorsal from the midpoint of the ovoid sources) dose (p = 0.044), and single or total point S dose by HDR-ICR (p = 0.019, each) mere significantly higher in patients who developed complication, whereas these factors did not significantly affect the probability of pelvic control. Multivariate analysis revealed that D was the independent predictor for the endpoint of actuarial complication rate (p = 0.047), No significant difference was noted in the product of L, D, and IV value (L x D x W) between patients with less than Grade 2 rectal complication and those with Grade 2-4. Conclusion: Depth of 6-Gy isodose volume determined three dimensionally (3D) has the predictive value of late rectal complications, This suggests that the shape of the high dose area in HDR-ICR influences the incidence of late rectal complications regardless of its volume. (C) 1998 Elsevier Science Inc.
引用
收藏
页码:615 / 621
页数:7
相关论文
共 50 条
[41]   Rectal bleeding after high-dose-rate brachytherapy combined with hypofractionated external-beam radiotherapy for localized prostate cancer: Impact of rectal dose in high-dose-rate brachytherapy on occurrence of grade 2 or worse rectal bleeding [J].
Akimoto, Tetsuo ;
Katoh, Hiroyuki ;
Kitamoto, Yoshizumi ;
Tamaki, Tomoaki ;
Harada, Kosaku ;
Shirai, Katsuyuki ;
Nakano, Takashi .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2006, 65 (02) :364-370
[42]   Side effects and complications of high dose-rate brachytherapy: literature review and our own observations [J].
Shchukina, E. O. ;
Biryukov, V. A. ;
Karyakin, O. B. ;
Ivanov, S. A. .
ONKOUROLOGIYA, 2024, 20 (03) :67-79
[43]   Urethral strictures following high-dose-rate brachytherapy for prostate cancer: Analysis of risk factors [J].
Hindson, Benjamin R. ;
Millar, Jeremy L. ;
Matheson, Bronwyn .
BRACHYTHERAPY, 2013, 12 (01) :50-55
[44]   High-dose rate brachytherapy for high-risk prostate cancer [J].
Schenck M. ;
Krause K. ;
Schwandtner R. ;
Haase I. ;
Fluehs D. ;
Friedrich J. ;
Jaeger T. ;
Boergermann C. ;
Ruebben H. ;
Stuschke M. .
Der Urologe, 2006, 45 (6) :715-722
[45]   Implementation of high-dose-rate brachytherapy for prostatic carcinoma in an unshielded operating room facility [J].
Elangovan, Arun ;
Husain, Siraj ;
McGeahy, Philip ;
Roumeliotis, Michael ;
Wu, Che Hsuan David ;
Wolfe, Nathan ;
Meyer, Tyler ;
Watt, Elizabeth ;
Martell, Kevin ;
Thind, Kundan .
BRACHYTHERAPY, 2021, 20 (01) :58-65
[46]   Low dose rate brachytherapy in lip carcinoma [J].
C. Conill ;
E. Verger ;
J. Marruecos ;
M. Vargas ;
A. Biete .
Clinical and Translational Oncology, 2007, 9 :251-254
[47]   Low dose rate brachytherapy in lip carcinoma [J].
Conill, C. ;
Verger, E. ;
Marruecos, J. ;
Vargas, M. ;
Biete, A. .
CLINICAL & TRANSLATIONAL ONCOLOGY, 2007, 9 (04) :251-254
[48]   GEOMETRICAL SPARING FACTORS FOR THE RECTUM AND BLADDER IN THE PREDICTION OF GRADE 2 AND HIGHER COMPLICATIONS AFTER HIGH-DOSE-RATE BRACHYTHERAPY FOR CERVICAL CANCER [J].
Chen, Shang-Wen ;
Liang, Ji-An ;
Hung, Yao-Ching ;
Yeh, Lian-Shung ;
Chang, Wei-Chun ;
Yang, Shih-Neng ;
Lin, Fang-Jen .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009, 75 (05) :1335-1343
[49]   High dose rate intracavitary brachytherapy for recurrent or residual lesions in the vaginal cuff: Results in post-hysterectomy patients with carcinoma of the cervix [J].
Ogino, I ;
Kitamura, T ;
Okamoto, N ;
Nakayama, H ;
Matsubara, S .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2001, 11 (01) :61-68
[50]   Extended-field radiotherapy and high-dose-rate brachytherapy in carcinoma of the uterine cervix - Clinical experience with and without concomitant chemotherapy [J].
Sood, BM ;
Gorla, GR ;
Garg, M ;
Anderson, PS ;
Fields, AL ;
Runowicz, CD ;
Goldberg, GL ;
Vikram, B .
CANCER, 2003, 97 (07) :1781-1788